Targeted Genetics announces issuance of additional adeno-associated virus (AAV) vector technology patent
"We believe that AAV vectors hold great promise in treating a wide variety of diseases," said H. Stewart Parker, President and Chief Executive Officer. "Targeted Genetics is pursuing several approaches, including the approach outlined in this patent, to expand the utility of AAV vectors. Utilizing sequences contained within the AAV genome to drive expression increases our flexibility with respect to vector design, which may allow us to deliver genes that might not ordinarily fit into a single AAV vector."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.